Atlas Trials

Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

Clinical trial NCT02928224 · COMPLETED

Trial details

NCT number
NCT02928224
Sponsor
Pfizer
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
BRAF V600E-mutant Metastatic Colorectal Cancer
Start date
2016-10-13
Primary completion
2019-02-11
Enrollment
702

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.